Skip to main content

Advertisement

SpringerLink
Log in

Management of the antiphospholipid syndrome

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Antiphospholipid antibodies are associated with a hypercoagulable state leading to a wide variety of systemic manifestations and obstetric complications. The different pathologic manifestations can be a result of arterial and venous thrombosis, microthrombotic angiopathy, embolization, obstetric disease, and non-thrombotic phenomenon. Presently, the treatment centers on anticoagulation. Two randomized prospective studies in patients with antiphospholipid syndrome with initial thromboembolic event support the target international normalized ratio of 2.0 to 3.0 for the prevention of future thrombotic events. With pregnancy, the combination of aspirin and heparin is still the standard of care. In addition, nonthrombotic features and any associated autoimmune disease may need to be treated. Underlying risk factors precipitating the thromboembolic phenomenon need to be addressed as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Petri M: Clinical and management aspects of the antiphospholipid antibody syndrome. In Dubois Lupus, edn 6. Edited by Wallace D, Fahn B. Philadelphia: Lippincott Williams & Wilkins; 2002:1093–1128.

    Google Scholar 

  2. Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminar y classification criteria for definitive antiphospholipid syndrome. Arthritis Rheum 1999, 42:1309–1311.

    Article  PubMed  CAS  Google Scholar 

  3. Sanna G, Bertolaccini ML, Cuadrado MJ, et al.: Central ner vous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology 2003, 42:200–213.

    Article  PubMed  CAS  Google Scholar 

  4. Levine JS, Branch W, Rauch J, et al.: The antiphospholipid syndrome. N Engl J Med 2002, 346:752–763. Exhaustive and excellent review of the APS which also includes detailed discussion of differential diagnosis and different clinical manifestations.

    Article  PubMed  CAS  Google Scholar 

  5. Petri M: Epidemiolog y of the antiphospholipid antibody syndrome. J Autoimmun 2000, 15:145–151.

    Article  PubMed  CAS  Google Scholar 

  6. De Groot PG, Derksen RHWM: Pathophysiolog y of antiphospholipid antibodies. Neth J Med 2004, 62:267–272.

    Google Scholar 

  7. Tenedios F, Erkan D, Lockshin MD: Cardiac involvement in the antiphospholipid syndrome. Lupus 2005, 14:691–696. Discussion of various cardiac manifestations of aPL including valv ular abnormalities and review of literature regarding management.

    Article  PubMed  CAS  Google Scholar 

  8. Karp DR: Complement and systemic lupus er ythematosus. Curr Opin Rheumatol 2005, 17:538–542.

    Article  PubMed  CAS  Google Scholar 

  9. Gomez-Puerta JA, Martin H, Amigo MC, et al.: Long-term follow up in 128 patients with primary antiphospholipid syndrome. Medicine 2005, 84:225–230.

    Article  PubMed  Google Scholar 

  10. Ramos-Casals M, Campoamor MT, Chamorro A, et al.: Hypocomplementemia in systemic lupus er ythematosus and primar y antiphospholipid syndrome: prevalence and clinical significance in 667 patients. Lupus 2004, 13:777–783.

    Article  PubMed  CAS  Google Scholar 

  11. Grion-Gonzalez JA, Del Rio EG, Rodriguez C, et al.:Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody. Prospective analysis of 404 individuals. J Rheumatol 2004, 31:1560–1567. Described initial presentation and prospective follow-up of 404 patients of which 226 had primar y or secondar y APS, the rest were asymptomatic carriers of aPL. Good description of initial presentation and risk factors identified during thrombotic events. Also shows the follow-up of laborator y abnormalities obser ved in during 36 month.

    Google Scholar 

  12. Maurizio T, Sarzi-Puttini P, Peretti R, et al.: Thrombotic risk factors in primar y antiphospholipid syndrome: a 5 year prospective study. Stroke 2005, 36:1490–1494.

    Article  Google Scholar 

  13. Groot PG, Derksen RHWM: Antiphospholipid antibodies: update on detection, pathophysiolog y and treatment. Curr Opin Hematol 2004, 11:165–169. Excellent recent review of the aPL antibodies; detection and treatment.

    Article  PubMed  Google Scholar 

  14. Erkan D, Merrill JT, Yazici Y, et al.: High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 2001, 44:1466–1467.

    Article  PubMed  CAS  Google Scholar 

  15. Ortel TL: Thrombosis and the antiphospholipid syndrome. Hematolog y. Hematology 2005, 462–468 www.asheducationbook.org/cig/reprint/2005/1/462

  16. Brunner HI, Chan WS, Ginsberg JS, et al.: Long term anticoagulation is preferable for patients with antiphospholipid syndrome; result of a decision analysis. J Rheumatol 2002, 29:490–501.

    PubMed  CAS  Google Scholar 

  17. Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303–330.

    PubMed  CAS  Google Scholar 

  18. Crowther MA, Ginsberg JS, Jullian J, et al.: A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133–1138. Prospective randomized clinical trial comparing the intensity of anticoagulation in patients with APS. In this study 114 patients were enrolled to receive anticoagulation with target INR of either 2.0 to 3.0 or a higher target INR in the range of 3.1 to 4.0. High intensity anticoagulation was not superior as compared with low intensity anticoagulation in preventing recurrent thrombotic events in this study. Patients who had experienced recurrent thrombosis on anticoagulation were excluded from this study.

    Article  PubMed  CAS  Google Scholar 

  19. Finazzi G, Marchioli R, Brancaccio V, et al.: A randomized clinical trial of high intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. J Thrombosis Haemost 2005, 3:848–853. Prospective randomized clinical trial comparing the intensity of anticoagulation in patients with APS. In this study 109 patients were enrolled to received anticoagulation with target INR of either 2.0 to 3.0 or a higher target INR of 3.0 to 4.5. High intensity anticoagulation was not superior as compared with low intensity anticoagulation in preventing recurrent thrombotic events in this study. Patients who had experienced recurrent thrombosis were excluded from this study.

    Article  CAS  Google Scholar 

  20. Asherson R A, Cervera R, De Groot PG, et al.: Catastrophic antiphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 2003, 12:530–534. This paper addresses the rare catastrophic antiphospholipid syndrome. Provides guidelines for recognization, classification and treatment.

    Article  PubMed  CAS  Google Scholar 

  21. Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antiphospholipid antibody syndrome. Clinical and laboratory features of 50 patients. Medicine 1998, 77:195–207.

    Article  PubMed  CAS  Google Scholar 

  22. Asherson RA, Cervera R, Piette JC, et al.: Catastrophic antiphospholipid antibody syndrome: clues to the pathogenesis from a series of 80 patients. Medicine 2001, 80:355–377.

    Article  PubMed  CAS  Google Scholar 

  23. Branch DW, Khamastha MA: Obstetric diagnosis, management and controversies. Obstet Gynecol 2003, 101:1333–1344.

    Article  PubMed  Google Scholar 

  24. Kitridov RC, Goodwin TM: The fetus in systemic lupus er ythematosus. In Dubois Lupus, edn 6. Edited by Wallace D, Hahn B. Philadelphia: Lippincott Williams and Wilkins; 2002:1027–1029.

    Google Scholar 

  25. Triolo G, Ferrante A, Accardo-Palumbo: IVIG in APS pregnancy. Lupus 2004, 13:731–735.

    Article  PubMed  CAS  Google Scholar 

  26. Branch DW, Silver R, Pierangeli S, et al.: Antiphospholipid antibodies other than lupus anticoagulant and anticardiolipin antibodies in women with recurrent pregnancy loss, fertile controls, and antiphospholipid syndrome. Obstet Gynecol 1997, 89:549–555.

    Article  PubMed  CAS  Google Scholar 

  27. Cervera R, Balasch J: The management of pregnant patients with antiphospholipid syndrome. Lupus 2004, 13:683–687.

    Article  PubMed  CAS  Google Scholar 

  28. Derksen RH, Khamashta MA, Branch DW: Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004, 50:1028–1039. Excellent and detailed review on management of pregnancy in patients with aPL. Exhaustive review of current literature with regards to aPL and obstetric complications.

    Article  PubMed  CAS  Google Scholar 

  29. Cowchock FS, Reese EA, Balaban D, et al.: Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low dose heparin treatment. Am J Obstet Gynecol 1992, 166:1318–1323.

    PubMed  CAS  Google Scholar 

  30. Rai R, Cohen H, Dave M, et al.: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997, 314:253–257.

    PubMed  CAS  Google Scholar 

  31. Farquharson RG, Quenby S, Greaves M: Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. Obstet Gynecol 2002, 100:408–413.

    Article  PubMed  CAS  Google Scholar 

  32. Noble LS, Kutteh WH, Lashey N, et al.: Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective multicenter controlled pilot study comparing treatment with low molecular weight heparin versus unfractionated heparin. Fertil Steril 2005, 83:684–690.

    Article  PubMed  CAS  Google Scholar 

  33. Empson M, Lassere M, Craig J, et al.: Prevention of recurrent miscarriage with antiphospholipid antibody or lupus anticoagulant. (systemic review). Cochrane Database Syst Rev 2005, Volume 4. This is a comprehensive meta-analysis of the major trials in the use of unfractionated heparin and aspirin in the management of recurrent miscarriage, discussing the statistical signif icance of the combined e xperience in improving outcomes in this population.

  34. Lockshin M, Tenedios F, Petri M, et al.: Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003, 12:518–523.

    Article  PubMed  CAS  Google Scholar 

  35. Turiel M, Sarzi-Puttini P, Peretti R, et al.: Five year follow up by transesophageal echocardiographic studies in primar y antiphospholipid syndrome. Am J Cardiol 2005, 96:574–579.

    Article  PubMed  Google Scholar 

  36. D’Cruz DP: Renal manifestation of the antiphospholipid syndrome. Lupus 2005, 14:45–48.

    Article  PubMed  CAS  Google Scholar 

  37. Korkmaz C, Kabukcuoglu S, Isiksoy S, et al.: Renal involvement in primar y antiphospholipid syndrome and its response to immunosuppressive treatment. Lupus 2003, 12:760–765.

    Article  PubMed  CAS  Google Scholar 

  38. Vaidya S, Sellers R, Kimball P, et al.: Frequency, potential risk and therapeutic intervention in end-stage renal disease. Patients with antiphospholipid antibody syndrome: a multicenter study. Transplantation 2000, 69:1348–1352.

    Article  PubMed  CAS  Google Scholar 

  39. Frances C, Niang S, Laffitte E, et al.: Dermatologic manifestation of the antiphospholipid syndrome. Arthritis Rheum 2005, 52:1785–1790.

    Article  PubMed  Google Scholar 

  40. Petri M: Hydroxychloroquine use in the Baltimore lupus cohort: effects of lipids, glucose, and thrombosis. Lupus 1996, 5(Suppl I):S16-S22.

    Article  PubMed  CAS  Google Scholar 

  41. Edwards MH, Pierangeli S, Liu XW, et al.: Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation 1997, 96:4380–4384.

    PubMed  CAS  Google Scholar 

  42. Toubi E, Kessel A, Rosner I, et al.: Quinacrine added to ongoing therapeutic regimens attenuates anticardilipin antibody production in SLE. Lupus 2003, 12:297–301.

    Article  PubMed  CAS  Google Scholar 

  43. Costedoat-Chalumeau N, Amoura Z, Huong DLT, et al.:Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev 2005, 4:111–115.

    Article  PubMed  CAS  Google Scholar 

  44. Statkute L, Traynor A, Oyama Y, et al.: Antiphospholipid syndrome in patients with systemic lupus erythematosus treated by autologous hemotopoietic stem cell transplantation. Blood, prepublished online 5, 2005; DOI 10.1182/blood-2005-01–0330.

  45. Ann ER, Lander G, Bidot CJ, et al.: Long term remission from life threatening hypercoagulable state associated with lupus anticoagulant following rituximab therapy. Am J Hematol 2005, 78:127–129.

    Article  Google Scholar 

  46. Erkan D, Cervera R, Asherson R A: Catastrophic antiphospholipid syndrome. Where do we stand. Arthritis Rheum 2003, 48:3320–3327.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Rheumatology, Washington Hospital Center, 110 Irving St, NW, 2A-66, 20010, Washington, DC, USA

    Arthur Weinstein MD

Authors
  1. Paul DeMarco MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Inderprit Singh MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arthur Weinstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arthur Weinstein MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

DeMarco, P., Singh, I. & Weinstein, A. Management of the antiphospholipid syndrome. Curr Rheumatol Rep 8, 114–120 (2006). https://doi.org/10.1007/s11926-006-0051-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-006-0051-1

Keywords

Search

Navigation